Subtype
Osteosarcoma
CI-CAN-00001321Explore in graph →
99 active trials6 approved drugs5 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001321Explore in graph →
Clinical trials
349 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (40)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT02011126 |
| Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
| withdrawn |
| Phase 2 |
| 0 |
| Children's Oncology GroupNETWORK |
| 0 |
| Aug 7, 2018 |
| clinicaltrials |
Data updated 22 days agoSource updated Dec 7, 2021source: clinicaltrials